ChemoTox is a pharmacogenetic test that delivers guidelines to chemotherapy dosage to minimize the risk of side effects.

And it's all done
with a simple swab.
Results in 3-5 days.

Over 9% of breast cancer patients are admitted to the hospital due to adverse reactions of chemotherapy.1

Studies show that 3 in 4 cancer patients will not respond to a given Oncology medication.2

Over 68% of patients receiving chemotherapy will suffer chemotherapy induced peripheral neuropathy within the first 30 days of treatment.3

$11.1 billion is spent on supportive care treatments, which help with the side effects of chemotherapy.4

ChemoTox easy to interpret reports empower physicians with actionable genetic information to customize chemotherapy dosage unique to each patient. With 3-5 days turnaround time, patients are likely to be on the right medication at the right dose more quickly.

One simple, non-invasive test gives you fast results that can dramatically improve your patient's quality of life.

Improves patient outcomes.

Reduces overall healthcare cost.

Reduces adverse drug events.

Eliminates trial and error approach to chemotherapy dosage selection.

It takes 3 simple steps to generate your personalized patient results in 3-5 business days.

  • Swab

  • Fill out requisition form


Your Patient's Personalized Report

ChemoTox easy to interpret reports empower physicians with actionable genetic information to customize chemotherapy dosage unique to each patient.


With a comprehensive gene list ChemoTox offers dosage guidelines for more medications and more patients delivering best in class clinical utility:


  • Paclitaxel (Taxol, Abraxane, Onxol)


  • Erlotinib (Tarceva)‡
  • Nilotinib (Tasigna)‡
  • Gefitinib (Iressa)‡
  • Pazopanib (Votrient)‡


  • Fluorouracil (Efudex, Adrucil, Carac, Fluoroplex)‡
  • Capecitabine (Xeloda)‡
  • Tegafur (Uftoral)


  • Methotrexate


  • Azathioprine (Imuran, Azasan, Azamun, Imurel)‡
  • Mercaptopurine (Purinethol)‡
  • Thioguanine (Tabloid)‡


  • Irinotecan (Camptosar)‡
  • Etoposide (Etopophos)
  • Raloxifene (Evista)
  • Irinotecan liposomal

* Pharmacogenomic biomarkers included in FDA-approved drug label. | ‡ FDA-approved drug that has a pharmacogenomics information in its label.

ChemoTox is empowered by evidence-based medicine.

Click here to open our library of sources

“Using ChemoTox for evaluating potential toxicities in chemotherapy will assist clinicians in either choosing less toxic chemotherapy or making dose adjustments upfront to avoid grade 3 and 4 toxicities.”

Chief of Gynecologic Oncology at UF Health Cancer Center - Orlando Health and Chair of Robotics and Minimally Invasive Surgical Quality at Winnie Palmer Hospital for Women and Babies

The insights provided by patients genetic information is now within your reach. Alpha Genomix is committed to finding affordable solutions for all patients. For further details, download our billing guide.

1. Molecular Medicine, Volume 7, Issue 5(1 May 2001) 201-204. | 2. Journal of Clinical Oncology Volume 20, Issue 24 (December 2002) 4636-4642.
3. Pain, Volume 155, issue 12 (December 2014), Pages 2461-2470 | 4. 2014 IMS Health Informatics